TargetBeta
CD7
CD7 molecule · also GP40, LEU-9, TP41, Tp40 · CD molecules
3 programs in company-led studies act on CD7, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Autologous Anti-CD7 CAR T Cells PA3-17rule | PersonGen BioTherapeutics (Suzhou) | phase 2 | 63 running | – | NCIt |
| Anti-CD7 CAR-T Cells RD13-02rule | Nanjing Bioheng Biotech | early phase 1 | 11 running | – | NCIt |
| UTAA07rule | PersonGen BioTherapeutics (Suzhou) | early phase 1 | 11 running | – | the studies' text |
Conditions their studies are in
- Diabetes Mellitus, Type 1, 1 program
- Lymphoma, 1 program
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 program
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, 1 program
- Scleroderma, Systemic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2027UTAA07 · PersonGen BioTherapeutics (Suzhou) · early phase 1 · NCT07338604
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.